GenFleet Therapeutics-B (02595) experienced a significant intraday decline of 11.85% on Tuesday, as the stock plummeted during the trading session.

The sharp drop followed the company's clarification regarding its Pan RAS inhibitor drug candidate GFH276. GenFleet stated that GFH276 was developed using independent, proprietary intellectual property and is unrelated to patent or trade secret disputes referenced in correspondence from Revolution Medicines on RAS inhibitors.

In its announcement, the company emphasized it has no exposure to infringement or trade secret risks tied to those disputes and highlighted its global patent portfolio for the Pan RAS program, with core patent protection projected through 2044.